This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
RNMT Polyclonal Antibody
catalog :
PA5-41778
quantity :
100 uL
price :
US 464.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot
citations: 1
product information
Product Type :
Antibody
Product Name :
RNMT Polyclonal Antibody
Catalog # :
PA5-41778
Quantity :
100 uL
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Affinity Chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
Western Blot: 0.2-1 ug/mL
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
RNMT belongs to the mRNA cap methyltransferase family. RNMT is a mRNA-capping methyltransferase that methylates the N7 position of the added guanosine to the 5'-cap structure of mRNAs. It binds RNA containing 5'-terminal GpppC.
Immunogen :
Synthetic peptide directed towards the C-terminal of human RNMT (aa 326-375).
Format :
Liquid
Applications w/Dilutions :
Western Blot: 0.2-1 ug/mL
Aliases :
2610002P10Rik; AI848273; cm1p; CMT1; CMT1c; hcm1p; hCMT1; hMet; Kiaa0398; MET; mKIAA0398; mRNA (guanine-7-)methyltransferase; mRNA (guanine-N(7)-)-methyltransferase; mRNA cap guanine-N7 methyltransferase; mRNA cap methyltransferase; RG7MT1; RNA (guanine-7-) methyltransferase; RNA guanine-7 methyltransferase; RNMT
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments